IN2014DN10538A - - Google Patents
Info
- Publication number
- IN2014DN10538A IN2014DN10538A IN10538DEN2014A IN2014DN10538A IN 2014DN10538 A IN2014DN10538 A IN 2014DN10538A IN 10538DEN2014 A IN10538DEN2014 A IN 10538DEN2014A IN 2014DN10538 A IN2014DN10538 A IN 2014DN10538A
- Authority
- IN
- India
- Prior art keywords
- disorders
- conditions
- group
- prodrug
- metabotropic glutamate
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010008748 Chorea Diseases 0.000 abstract 1
- 208000012239 Developmental disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000002740 Muscle Rigidity Diseases 0.000 abstract 1
- 208000029033 Spinal Cord disease Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000012601 choreatic disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003514 metabotropic receptor agonist Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
- C07D317/40—Vinylene carbonate; Substituted vinylene carbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Provided are a fluorine containing amino acid prodrug represented by general formula (I) that makes a fluorine containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug or a pharmacologically acceptable salt thereof. More specifically provided is a prodrug that increases the in vivo exposure and heightens the oral absorbability and other such mucosal absorbability of a novel compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of conditions in which group 2 metabotropic glutamate receptors are said to participate such as: schizophrenia anxiety disorder and related conditions depression bipolar disorder epilepsy developmental disorders sleep disorders and other such neuropsychiatric conditions; and drug dependence cognitive disorders Alzheimer s disease Huntington s chorea Parkinson s disease movement disorders associated with muscular rigidity cerebral ischemia cerebral insufficiency spinal cord disorders cephalopathy and other such neurological conditions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012126162 | 2012-06-01 | ||
| JP2013052574 | 2013-03-15 | ||
| PCT/JP2013/065202 WO2013180271A1 (en) | 2012-06-01 | 2013-05-31 | Prodrug of fluorine-containing amino acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10538A true IN2014DN10538A (en) | 2015-08-21 |
Family
ID=49673454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10538DEN2014 IN2014DN10538A (en) | 2012-06-01 | 2013-05-31 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9428483B2 (en) |
| EP (1) | EP2857385B1 (en) |
| JP (1) | JP5979230B2 (en) |
| KR (1) | KR102062936B1 (en) |
| CN (1) | CN104334524B (en) |
| AU (1) | AU2013268303B2 (en) |
| BR (1) | BR112014029478B1 (en) |
| CA (1) | CA2875080C (en) |
| CY (1) | CY1119646T1 (en) |
| DK (1) | DK2857385T3 (en) |
| ES (1) | ES2637986T3 (en) |
| HK (1) | HK1202526A1 (en) |
| HR (1) | HRP20171373T1 (en) |
| HU (1) | HUE034513T2 (en) |
| IL (1) | IL235897B (en) |
| IN (1) | IN2014DN10538A (en) |
| LT (1) | LT2857385T (en) |
| ME (1) | ME02833B (en) |
| MX (1) | MX355161B (en) |
| MY (1) | MY169069A (en) |
| NO (1) | NO2857385T3 (en) |
| NZ (1) | NZ702237A (en) |
| PH (1) | PH12014502670A1 (en) |
| PL (1) | PL2857385T3 (en) |
| PT (1) | PT2857385T (en) |
| RS (1) | RS56328B1 (en) |
| RU (1) | RU2639868C1 (en) |
| SG (1) | SG11201407973SA (en) |
| SI (1) | SI2857385T1 (en) |
| TW (1) | TWI602801B (en) |
| WO (1) | WO2013180271A1 (en) |
| ZA (1) | ZA201408857B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591931A1 (en) | 2013-04-09 | 2016-05-31 | Ликсте Байотекнолоджи, Инк. | COMPOSITIONS OF OXABICYCLOPTANES AND OXABITICLOCEPTENS |
| JP5983713B2 (en) * | 2013-11-29 | 2016-09-06 | 大正製薬株式会社 | Pharmaceuticals containing prodrugs of fluorine-containing amino acids |
| JP5983714B2 (en) * | 2013-11-29 | 2016-09-06 | 大正製薬株式会社 | Crystal form of fluorine-containing amino acid prodrug and process for producing the same |
| MX2016008110A (en) * | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Pyrazole derivatives and uses thereof as inhibitors of dlk. |
| EP3736275A1 (en) * | 2015-05-15 | 2020-11-11 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs for use in treating cancer |
| DK3445743T3 (en) | 2016-04-18 | 2021-10-18 | Taisho Pharmaceutical Co Ltd | PRODUCT OF AMINO ACID DERIVATIVE |
| JP7314494B2 (en) * | 2017-10-17 | 2023-07-26 | 大正製薬株式会社 | Pharmaceuticals containing prodrugs of amino acid derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4171549B2 (en) * | 1998-01-28 | 2008-10-22 | 大正製薬株式会社 | Fluorine-containing amino acid derivatives |
| ES2191412T3 (en) * | 1998-01-28 | 2003-09-01 | Taisho Pharmaceutical Co Ltd | DERIVATIVES OF AMINO ACIDS CONTAINING FLUOR. |
| KR100567288B1 (en) | 1998-12-18 | 2006-04-04 | 다이쇼 세이야꾸 가부시끼가이샤 | Intermediates and Process for Producing Fluorine-Containing Amino Acid Compound by Using The Same |
| JP4783967B2 (en) * | 1999-07-21 | 2011-09-28 | 大正製薬株式会社 | Pharmaceuticals containing fluorine-containing amino acid derivatives as active ingredients |
| AU2002359923B2 (en) * | 2001-12-27 | 2007-12-20 | Taisho Pharmaceutical Co., Ltd. | 6-fluorobicyclo[3.1.0]hexane derivatives |
| CN101362793A (en) | 2002-06-11 | 2009-02-11 | 伊莱利利公司 | Prodrugs of excitatory amino acids |
| PT1517915E (en) | 2002-06-11 | 2009-04-09 | Lilly Co Eli | Prodrugs of excitatory amino acids |
| JP5983713B2 (en) * | 2013-11-29 | 2016-09-06 | 大正製薬株式会社 | Pharmaceuticals containing prodrugs of fluorine-containing amino acids |
| JP5983714B2 (en) * | 2013-11-29 | 2016-09-06 | 大正製薬株式会社 | Crystal form of fluorine-containing amino acid prodrug and process for producing the same |
-
2013
- 2013-05-31 SG SG11201407973SA patent/SG11201407973SA/en unknown
- 2013-05-31 PL PL13797352T patent/PL2857385T3/en unknown
- 2013-05-31 KR KR1020147032686A patent/KR102062936B1/en active IP Right Grant
- 2013-05-31 MX MX2014014642A patent/MX355161B/en active IP Right Grant
- 2013-05-31 AU AU2013268303A patent/AU2013268303B2/en active Active
- 2013-05-31 ES ES13797352.5T patent/ES2637986T3/en active Active
- 2013-05-31 EP EP13797352.5A patent/EP2857385B1/en active Active
- 2013-05-31 ME MEP-2017-207A patent/ME02833B/en unknown
- 2013-05-31 RS RS20170883A patent/RS56328B1/en unknown
- 2013-05-31 NZ NZ702237A patent/NZ702237A/en unknown
- 2013-05-31 JP JP2014518753A patent/JP5979230B2/en active Active
- 2013-05-31 CN CN201380028764.5A patent/CN104334524B/en active Active
- 2013-05-31 LT LTEP13797352.5T patent/LT2857385T/en unknown
- 2013-05-31 MY MYPI2014703559A patent/MY169069A/en unknown
- 2013-05-31 US US14/403,790 patent/US9428483B2/en active Active
- 2013-05-31 HU HUE13797352A patent/HUE034513T2/en unknown
- 2013-05-31 SI SI201330754T patent/SI2857385T1/en unknown
- 2013-05-31 DK DK13797352.5T patent/DK2857385T3/en active
- 2013-05-31 BR BR112014029478-0A patent/BR112014029478B1/en active IP Right Grant
- 2013-05-31 RU RU2014153509A patent/RU2639868C1/en active
- 2013-05-31 NO NO13797352A patent/NO2857385T3/no unknown
- 2013-05-31 PT PT137973525T patent/PT2857385T/en unknown
- 2013-05-31 IN IN10538DEN2014 patent/IN2014DN10538A/en unknown
- 2013-05-31 TW TW102119430A patent/TWI602801B/en active
- 2013-05-31 CA CA2875080A patent/CA2875080C/en active Active
- 2013-05-31 WO PCT/JP2013/065202 patent/WO2013180271A1/en active Application Filing
-
2014
- 2014-11-25 IL IL235897A patent/IL235897B/en active IP Right Grant
- 2014-11-28 PH PH12014502670A patent/PH12014502670A1/en unknown
- 2014-12-03 ZA ZA2014/08857A patent/ZA201408857B/en unknown
-
2015
- 2015-03-31 HK HK15103203.0A patent/HK1202526A1/en unknown
-
2017
- 2017-09-13 HR HRP20171373TT patent/HRP20171373T1/en unknown
- 2017-10-11 CY CY20171101062T patent/CY1119646T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502670A1 (en) | Prodrug of fluorine - containing amino acid | |
| PH12018502211A1 (en) | Prodrug of amino acid derivative | |
| CY1118021T1 (en) | AZOLI PRODUCTION | |
| MY167396A (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| MX2013006715A (en) | Pyrazole derivative. | |
| PH12015500398B1 (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| MX2013011290A (en) | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease. | |
| PH12014502178A1 (en) | Fused azole derivative | |
| PH12015502692A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
| MX2013003633A (en) | 1,2,4-triazolone derivative. | |
| TN2016000447A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands. | |
| PH12015500346A1 (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| PH12015500496A1 (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| IL202282A0 (en) | Prolinamide-tetrazole derivatives as nk3 receptor antagonists | |
| PH12017502128A1 (en) | Ethynyl derivatives | |
| TH147941A (en) | Prodes of amino acids containing fluorine | |
| UA99789C2 (en) | Choline salts of succinic acid for the treatment of depression, anxiety, schizophrenia, sleep disorder, or epilepsy |